Table 1 Clinico-pathological characteristics of patient cohort
Feature | Frequency n (%) | ||
|---|---|---|---|
Ductal carcinoma (n = 894) | Lobular carcinoma (n = 164) | ||
pT stage | pT1 | 369 (41.3) | 52 (31.7) |
pT2 | 475 (53.1) | 90 (54.9) | |
pT3 | 50 (5.6) | 22 (13.4) | |
pN stage | pN0 | 485 (54.3) | 90 (54.9) |
pN1 | 340 (38.0) | 67 (40.8) | |
pN2 | 69 (7.7) | 7 (4.3) | |
Clinical stage | IA | 254 (28.4) | 39 (23.8) |
IIA | 325 (36.4) | 54 (32.9) | |
IIB | 211 (23.6) | 42 (25.6) | |
IIIA | 104 (11.6) | 29 (17.7) | |
BRE grade | G1 | 181 (20.4) | 24 (14.7) |
G2 | 372 (41.9) | 118 (72.4) | |
G3 | 334 (37.7) | 21 (12.9) | |
ER status | Negative | 200 (23.7) | 22 (14.4) |
Positive | 645 (76.3) | 131 (85.6) | |
PR status | Negative | 346 (52.6) | 65 (54.6) |
Positive | 312 (47.4) | 54 (45.4) | |
Her-2/neu | 0 and 1+ | 680 (83.1) | 130 (94.2) |
2+ and 3+ | 138 (16.9) | 8 (5.8) | |
Molecular Subtypes | Luminal A | 160 (40.1) | 30 (48.4) |
Luminal B | 7 (1.8) | 0 (0.0) | |
Her2/neu | 64 (16.0) | 3 (4.8) | |
Triple Negative | 168 (42.1) | 29 (46.8) | |
Disease-specific survival | death from breast cancer | 72 (8.7) | 9 (5.8) |
Censored | 760 (91.3) | 145 (94.2) | |
5-year (95%CI) | 94.0 (92-96) | 97.0 (92-99) | |
Overall survival | Death | 172 (19.4) | 34 (21.3) |
Censored | 714 (80.6) | 126 (78.7) | |
5-year (95%CI) | 85.6 (83-88) | 87.8 (81-92) | |
Age at diagnosis (y) | median | 62 | 64 |
Minimum-maximum | 28-94 | 38-90 | |